Narcolepsy Drug Gets FDA Orphan Designation

Post Date: 
12 July 2016

The FDA has granted an Orphan Drug Designation for Mazindol, to treat Narcolepsy. 

 
Mazindol is a norepinephrine and dopamine reuptake inhibitor which serves as a wake-promoting agent. A critical part for an effective treatment of Narcolepsy is Rebalancing dysfunctional central nervous system (CNS) noradrenergic and dopaminergic systems. Currently, Mazindol is in a phase II Proof-of-Concept clinical trial evaluating the effectiveness of the drug in adults with Attention Deficit Hyperactivity Disorder (ADHD).
Read more here